

=> file medline biosis biotechno

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.00

1.15

FILE 'MEDLINE' ENTERED AT 16:00:14 ON 09 JUN 2000

FILE 'BIOSIS' ENTERED AT 16:00:14 ON 09 JUN 2000

COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'BIOTECHNO' ENTERED AT 16:00:14 ON 09 JUN 2000

COPYRIGHT (C) 2000 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s osteoprotegrin

L1 6 OSTEOPROTEGRIN

=> dup rem l1

PROCESSING COMPLETED FOR L1

L2 6 DUP REM L1 (0 DUPLICATES REMOVED)

=> d ibib abs 1-6

L2 ANSWER 1 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1999:322859 BIOSIS

DOCUMENT NUMBER: PREV199900322859

TITLE: Osteoprotegerin: Positive and negative regulation of osteoclastogenesis and bone mass.

AUTHOR(S): Lacey, D. L. (1); Hsu, H. (1); Penninger, J. (1); Simonet, W. S. (1); Dunstan, C. R. (1); Boyle, M. (1); Boyle, W. J. (1)

CORPORATE SOURCE: (1) Amgen, Inc, Thousand Oaks, CA, 91320 USA

SOURCE: FASEB Journal, (April 23, 1999) Vol. 13, No. 7, pp.

A1585.

Meeting Info.: Annual Meeting of the American Societies

for

Experimental Biology on Biochemistry and Molecular Biology
99 San Francisco, California, USA May 16-20, 1999 American Societies for Experimental Biology

. ISSN: 0892-6638.

DOCUMENT TYPE: Conference

LANGUAGE: English

L2 ANSWER 2 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS

ACCESSION NUMBER: 1999:444358 BIOSIS

DOCUMENT NUMBER: PREV199900444358

TITLE: Polymorphism in the promoter region of the human gene for osteoprotegerin: Correlation with bone mineral density.

AUTHOR(S): Brandstrom, H. (1); Stiger, F. (1); Michaelsson, K.; Gillberg, P. (1); Ljunghall, S. (1); Ljunggren, O. (1); Kindmark, A. (1)

CORPORATE SOURCE: (1) Medical Sciences, Uppsala Sweden

SOURCE: Journal of Bone and Mineral Research, (Sept., 1999) Vol. 14, No. SUPPL. 1, pp. S334.

Meeting Info.: Twenty-First Annual Meeting of the American Society for Bone and Mineral Research St. Louis, Missouri, USA September 30-October 4, 1999 American Society for Bone and Mineral Research

. ISSN: 0884-0431.

DOCUMENT TYPE: Conference
LANGUAGE: English

L2 ANSWER 3 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS
ACCESSION NUMBER: 1999:431081 BIOSIS
DOCUMENT NUMBER: PREV199900431081
TITLE: In vivo demonstration that parathyroid hormone (hPTH 1-38) inhibits the expression of **osteoprotegrin** (OPG) in bone with the kinetics of an immediate early gene.
AUTHOR(S): Onyia, J. E. (1); Miles, R. R. (1); Halladay, D. L. (1); Chandrasekhar, S. (1); Martin, T. J. (1)
CORPORATE SOURCE: (1) Endocrine Division, Lilly Research Labs, Indianapolis, IN USA
SOURCE: Journal of Bone and Mineral Research, (Sept., 1999) Vol. 14, No. SUPPL. 1, pp. S166.
Meeting Info.: Twenty-First Annual Meeting of the American Society for Bone and Mineral Research St. Louis, Missouri, USA September 30-October 4, 1999 American Society for Bone and Mineral Research
. ISSN: 0884-0431.
DOCUMENT TYPE: Conference
LANGUAGE: English

L2 ANSWER 4 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS
ACCESSION NUMBER: 1999:431061 BIOSIS
DOCUMENT NUMBER: PREV199900431061
TITLE: Characterization of osteoclast precursors in human peripheral blood.
AUTHOR(S): Shalhoub, V. (1); Elliott, G. (1); Chiu, L. (1); Manoukian, R. (1); Kelley, M. (1); Hawkins, N. (1); Dunstan, C. R. (1); Boyle, W. J. (1); Lacey, D. L. (1)
CORPORATE SOURCE: (1) Amgen, Inc., Thousand Oaks, CA USA
SOURCE: Journal of Bone and Mineral Research, (Sept., 1999) Vol. 14, No. SUPPL. 1, pp. S148.
Meeting Info.: Twenty-First Annual Meeting of the American Society for Bone and Mineral Research St. Louis, Missouri, USA September 30-October 4, 1999 American Society for Bone and Mineral Research
. ISSN: 0884-0431.
DOCUMENT TYPE: Conference
LANGUAGE: English

L2 ANSWER 5 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS
ACCESSION NUMBER: 1998:470107 BIOSIS
DOCUMENT NUMBER: PREV199800470107
TITLE: Presence of osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluids from patients with rheumatoid arthritis.
AUTHOR(S): Kotake, Shigeru (1); Udagawa, Nobuyuki; Takahashi, Naoyuki; Yano, Kazuki; Tsuda, Eisuke; Higashio, Kanji; Kamatani, Naoyuki (1); Suda, Tatsuo
CORPORATE SOURCE: (1) Tokyo Women's Med. Univ., Tokyo 162 Japan
SOURCE: Arthritis & Rheumatism, (Sept., 1998) Vol. 41, No. 9 SUPPL., pp. S320.
Meeting Info.: 62nd National Scientific Meeting of the American College of Rheumatology and the 33rd National Scientific Meeting of the Association of Rheumatology Health Professionals San Diego, California, USA November 8-12, 1998 American College of Rheumatology
. ISSN: 0004-3591.
DOCUMENT TYPE: Conference
LANGUAGE: English

L2 ANSWER 6 OF 6 BIOSIS COPYRIGHT 2000 BIOSIS
ACCESSION NUMBER: 1997:239635 BIOSIS
DOCUMENT NUMBER: PREV199799538838
TITLE: **Osteoprotegrin**: A novel, secreted member of the

tumor necrosis factor receptor superfamily profoundly
inhibits bone resorption in mice.

AUTHOR(S): Dunstan, C. R.; Derosé, M.; Simonet, W. S.; Tarpley, J.;
Kaufman, S.; Nguyen, H.; Hill, D.; Capparelli, C.; Boyle,
W. J.; Lacey, D. L.

CORPORATE SOURCE: Amgen, Thousand Oaks, CA USA

SOURCE: Bone (New York), (1997) Vol. 20, No. 4 SUPPL., pp. 11S.
Meeting Info.: 25th European Symposium on Calcified

Tissues
Harrogate, England, UK April 25-29, 1997
ISSN: 8756-3282.

DOCUMENT TYPE: Conference; Abstract

LANGUAGE: English

=> s opg3

L3 2 OPG3

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 1 DUP REM L3 (1 DUPLICATE REMOVED)

=> d ibib abs

L4 ANSWER 1 OF 1 MEDLINE DUPLICATE 1

ACCESSION NUMBER: 97200863 MEDLINE

DOCUMENT NUMBER: 97200863

TITLE: Epidemiological features of first-visit outpatients in
Japan: comparison with general population and variation by
sex, age, and season.

AUTHOR: Inoue M; Tajima K; Hirose K; Hamajima N; Takezaki T;
Kuroishi T; Tominaga S

CORPORATE SOURCE: Division of Epidemiology, Aichi Cancer Center Research
Institute, Nagoya, Japan.

SOURCE: JOURNAL OF CLINICAL EPIDEMIOLOGY, (1997 Jan) 50 (1) 69-77.
Journal code: JCE. ISSN: 0895-4356.

PUB. COUNTRY: ENGLAND: United Kingdom
(CLINICAL TRIAL)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199705

ENTRY WEEK: 19970504

AB To evaluate the methodological issues in using first-visit outpatients as
controls in epidemiological studies, the features of general lifestyles
of
non-cancer outpatients at Aichi Cancer Center Hospital (ACCH) were
compared with those of the general population, and their variation by
sex,
age, and season was determined by using a self-administered
questionnaire.
The study included 1231 subjects randomly selected from the Nagoya
electoral roll (CRG), and three groups of non-cancer ACCH outpatients
living in Nagoya; 800 from the period September to December 1992 (OPG1),
2326 from January to December 1992 (OPG2), and 12,243 from January 1991
to
December 1992 (OPG3). In the younger age group, the proportion
of current smokers was higher in the CRG than in the OPGs. In the older
age groups, the proportion of those who consumed fresh vegetables and
fruit everyday was higher in the OPGs than in the CRG. For other items,
the features of the OPGs were not significantly different from those of
the CRG. Among the OPG3, there were differences in the features
of general lifestyles between sexes and consumption of several food items
varied with age. Seasonal variation, however, was only observed in the
specific food items where supply varied seasonally. It was concluded
that,

with due consideration of age, sex, and season in the analysis, it is feasible to use non-cancer outpatients as controls in epidemiological studies.

=> s TNFRsol

L5 0 TNFRSOL

=> s tnfr sol?

L6 5 TNFR SOL?

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 2 DUP REM L6 (3 DUPLICATES REMOVED)

=> d ibib abs 1-2

L7 ANSWER 1 OF 2 MEDLINE DUPLICATE 1

ACCESSION NUMBER: 1999226867 MEDLINE

DOCUMENT NUMBER: 99226867

TITLE: Inhibition of tumor necrosis factor alpha-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and

interleukin-13

in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways.

AUTHOR: Alaaeddine N; Di Battista J A; Pelletier J P; Kiansa K; Cloutier J M; Martel-Pelletier J

CORPORATE SOURCE: University of Montreal, and Centre Hospitalier de l'Universite de Montreal, Quebec, Canada.

SOURCE: ARTHRITIS AND RHEUMATISM, (1999 Apr) 42 (4) 710-8. Journal code: 90M. ISSN: 0004-3591.

PUB. COUNTRY: United States Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 199907

ENTRY WEEK: 19990702

AB OBJECTIVE: To investigate the effects of the antiinflammatory cytokines interleukin-4 (IL-4), IL-10, and IL-13 on tumor necrosis factor alpha (TNFalpha)-induced prostaglandin E2 (PGE2) release in the cellular signaling cascade on human osteoarthritis (OA) synovial fibroblasts. METHODS: Human OA synovial fibroblasts were cultured to explore the

impact

of IL-4, IL-10, and IL-13 on TNFalpha binding to TNF receptors (TNFR), soluble TNFR (sTNFR), cytoplasmic phospholipase A2 (cPLA2), and cyclooxygenase-2 (COX-2) production, and on the binding activity of the transcription factors nuclear factor kappaB (NF-kappaB), CCAAT-enhancer binding protein (C/EBP), activator protein 2 (AP-2), and cyclic AMP response element-binding protein (CREB). RESULTS: IL-4, IL-10, and IL-13 at 5 ng/ml dramatically reduced TNFalpha-induced PGE2 release

by

approximately 90% ($P < 0.0001$). IL-4 up-regulated the level of TNFalpha-induced TNFR by 47% ($P < 0.06$), while IL-10 down-regulated it by 71% ($P < 0.02$); IL-13 had no effect. Although statistical significance

was

not reached, all 3 cytokines up-regulated the basal level of sTNFR-55. IL-4 and IL-10, while not altering the basal level of sTNFR-75, significantly increased the TNFalpha-stimulated release of sTNFR-75.

IL-4,

IL-10, and IL-13 reduced the TNFalpha-induced COX-2 level, and IL-4 and IL-10 reduced the cPLA2 level. IL-4 had no effect on TNFalpha up-regulation of NF-kappaB, and a slight decrease was noted with IL-10

and

IL-13 at the highest concentration used (5 ng/ml). IL-4 and IL-13

decreased the TNF α -induced C/EBP accumulation in a dose-dependent manner, while IL-10 up-regulated its basal level. AP-2 and G β 3 were not induced by TNF α . CONCLUSION: The results indicate that these antiinflammatory cytokines reversed the TNF α -induced release of PGE2 by OA synovial fibroblasts, by acting at various levels of the TNF α -dependent signaling cascade. These data shed new light on the mechanisms by which these cytokines reduce inflammatory processes.

L7 ANSWER 2 OF 2 MEDLINE
 ACCESSION NUMBER: 96199244 MEDLINE
 DOCUMENT NUMBER: 96199244
 TITLE: Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects.
 AUTHOR: Medvedev A E; Espevik T; Ranges G; Sundan A
 CORPORATE SOURCE: Institute of Cancer Research and Molecular Biology, Trondheim, Norway.
 SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1996 Apr 19) 271 (16) 9778-84.
 Journal code: HIV. ISSN: 0021-9258.
 PUB. COUNTRY: United States
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals; Cancer Journals
 ENTRY MONTH: 199608

AB The role for the two tumor necrosis factor (TNF) receptors in discriminating TNF and lymphotoxin alpha (LTalpha) effects has been studied. TNF and LTalpha were equally mitogenic in Fs4 fibroblasts, which express a high amount of the p55 compared to the p75 TNF receptors (TNFRs). In contrast, TNF was more potent than LTalpha in mediating gene regulation and cytotoxicity in SW480-betaGal cells and KYM-1 cells, which have a high p75/p55 TNFR ratio. Both TNF and LTalpha showed comparable affinities for the two TNFRs. However, in contrast to LTalpha, TNF dissociated rapidly from the p75 TNFR, whereas both cytokines dissociated slowly from the p55 TNFR. Soluble p55 TNFR was much more potent than soluble p75 TNFR in inhibiting TNF cytotoxicity, whereas both soluble receptors moderately decreased LTalpha-mediated cytotoxicity with comparable efficacy. Antagonistic monoclonal antibodies against either TNFR types markedly inhibited TNF effects. However, only the p55 TNFR antagonistic antibody significantly decreased LTalpha-mediated cytotoxicity and cytomegalovirus promoter activation, whereas blocking of the p75 TNFR enhanced the LTalpha effects. These data suggest that whereas the p75 TNFR can both directly propagate TNF signals and "pass" TNF to the p55 TNFR, it attenuates LTalpha and may serve as a decoy receptor for this cytokine.

=> s flint

L8 876 FLINT

=> s l8 and tn timer

L9 0 L8 AND TNF

=> s l8 and fas

L10 0 L8 AND FAS

=> s l8 and fasl

L11 0 L8 AND FASL

=> s l8 and tn timer

L12 0 L8 AND TNFR

. => d ti 1-8 l8

L8 ANSWER 1 OF 876 MEDLINE

TI Detection and mapping of quantitative trait loci for haloperidol-induced catalepsy in a C57BL/6J x DBA/2J F2 intercross.

L8 ANSWER 2 OF 876 MEDLINE

TI Influence of arsenic on proliferation and differentiation of rat bud cells
in vitro.

L8 ANSWER 3 OF 876 MEDLINE

TI Effect of fluoride on proliferation and differentiation in rat and mouse embryo bud cell in vitro.

L8 ANSWER 4 OF 876 MEDLINE

TI Fine mapping and characterization of linked quantitative trait loci involved in the transition of the maize apical meristem from vegetative to
generative structures.

L8 ANSWER 5 OF 876 MEDLINE

TI The TD6 level lithic industry from Gran Dolina, Atapuerca (Burgos, Spain):
production and use.

L8 ANSWER 6 OF 876 MEDLINE

TI Effect of wheat and corn variety on fiber digestion in beef steers fed high-grain diets.

L8 ANSWER 7 OF 876 MEDLINE

TI Hyperproduction of recombinant ferredoxins in escherichia coli by coexpression of the ORF1-ORF2-iscS-iscU-iscA-hscB-hs cA-fdx-ORF3 gene cluster.

L8 ANSWER 8 OF 876 MEDLINE

TI Influence of grain source on ruminal characteristics and rate, site, and extent of digestion in beef steers.

=> s fasl

L13 3108 FASL

=> s fas

L14 15262 FAS

=> s l13 and l14

L15 2805 L13 AND L14

=> l15 and tnfr

L15 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l15 and tnfr

L16 64 L15 AND TNFR

=> s l16 and review

L17 2 L16 AND REVIEW

=> dup rem 117

PROCESSING COMPLETED FOR L17
L18 2 DUP REM L17 (0 DUPLICATES REMOVED)

=> d ibib abs 1-2

L18 ANSWER 1 OF 2 MEDLINE
ACCESSION NUMBER: 2000136452 MEDLINE
DOCUMENT NUMBER: 20136452
TITLE: Molecular and cellular mechanisms regulating T and B cell apoptosis through **Fas/FasL** interaction.
AUTHOR: Ju S T; Matsui K; Ozdemirli M
CORPORATE SOURCE: Department of Medicine, Boston University School of Medicine, MA 02118, USA.
CONTRACT NUMBER: R01-36938
SOURCE: INTERNATIONAL REVIEWS OF IMMUNOLOGY, (1999) 18 (5-6) 485-513. Ref: 153
Journal code: IRI. ISSN: 0883-0185.
PUB. COUNTRY: Switzerland
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200005
ENTRY WEEK: 20000501

AB **Fas** (CD95) and **Fas** ligand (**FasL**) are a receptor/ligand pair critically involved in lymphocyte homeostasis and peripheral tolerance such that genetic defect in either **Fas** or **FasL** results in an autoimmune lymphoproliferative syndrome. **Fas** is a type I transmembrane protein and a member of the tumor necrosis factor receptor (**TNFR**) family whereas **FasL** is a type II transmembrane protein and a member of **TNF** family. Binding of **Fas** by **FasL** induces apoptosis of the **Fas**-expressing cells. In the past few years, **Fas/FasL** interaction has been connected to a series of important phenomena previously viewed as independent immune processes. The activation-induced T cell death (AICD) and the **FasL**-mediated cytotoxicity by activated T cells are two critical mechanisms that can account for most of these phenomena. It is in the context of the two mechanisms that we discuss in this **review** the molecular and cellular events that occur during T/T and T/B interactions that account for the down-regulation of the immune response. We have also discussed recent advances in the areas of **FasL** gene regulation, lymphokine regulation of AICD, and regulation of B cell susceptibility to **FasL**. Investigation in these areas should help elucidate the role of **Fas/FasL** in the complex network of regulatory mechanisms that control immune response and autoimmunity.

L18 ANSWER 2 OF 2 BIOTECHNO COPYRIGHT 2000 Elsevier Science B.V.
ACCESSION NUMBER: 1995:25179481 BIOTECHNO
TITLE: Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas
AUTHOR: Gruss H.-J.; Dower S.K.
CORPORATE SOURCE: DMOAMB, UKRV-RRK, Freie University Berlin, Lindenberger Weg 80, D-13122 Berlin, Germany.
SOURCE: Blood, (1995), 85/12 (3378-3404)
CODEN: BLOOAW ISSN: 0006-4971
DOCUMENT TYPE: Journal; General Review
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English
AN 1995:25179481 BIOTECHNO
AB The **TNF** receptor superfamily members are all type I membrane glycoproteins with typical homology in the extracellular domain of

variable numbers of cysteine-rich repeats (overall homologies, 25% to 30%). In contrast, the TNF ligand superfamily members (with the exception of LT.alpha.) are type II membrane glycoproteins with homology to TNF in the extracellular domain (overall homologies, 20%). TNF and LT.alpha. are trimeric proteins and are composed of .beta.-strands forming a .beta.-jellyroll. The homology of the .beta.-strand regions for the TNF ligand superfamily members suggest a similar .beta.-sandwich structure and possible trimeric or multimeric complex formation for most or all members. A genetic linkage, as evidence for evolutionary relatedness, is found by chromosomal cluster of **TNFR** p80, CD30, 4-1BB, and OX40 for 1p36; **TNFR** p60, **TNFR**-RP, and CD27 for 12p13; TNF, LT.alpha., and LT.beta. for 6 (MHC locus); CD27L and 4-1BBL for 19p13; and **FASL** and OX40L for 1q25. Of the TNF ligand superfamily, TNF, LT.alpha., and LT.alpha. and their receptors (**TNFR** p60, **TNFR** p80, and **TNFR**-RP) interact in a complex fashion of cross-binding. However, the other family members presently have a one ligand/one receptor binding principle (CD27/CD27L, CD30/CD30L, CD40/CD40L, 4-1BB/4-1BBL, OX40/gp34, and **FAS**/**FASL**). In general, the members of the TNF ligand superfamily mediate interaction between different hematopoietic cells, such as T cell/B cell, T cell/monocyte, and T cell/T cell. Signals can be transduced not only through the receptors but also through at least some of the ligands. The transduced signals can be stimulatory or inhibitory depending on the target cell or the activation state. Taken together, TNF superfamily ligands show for the immune response an involvement in the induction of cytokine secretion and the upregulation of adhesion molecules, activation antigens, and costimulatory proteins, all known to amplify stimulatory and regulatory signals. On the other hand, differences in the distribution, kinetics of induction, and requirements for induction support a defined role for each of the ligands for T-cell-mediated immune responses. The shedding of members of the TNF receptor superfamily could limit the signals mediated by the corresponding ligands as a functional regulatory mechanism. Induction of cytotoxic cell death, observed for TNF, LT.alpha., CD30L, CD95L and 4-1BBL, is another common functional feature of this cytokine family. Further studies have to identify unique versus redundant biologic and physiologic functions for each of the TNF superfamily ligands. Primary H-RS cells can express TNF, LT.alpha., and CD27L but not CD30L and CD40L, in addition to IL-1.alpha., IL-5, IL-6, IL-9, and M-CSF. In addition, H-RS cells express high copy numbers of several cytokine receptors such as IL-2R (p55, p75, and p64 subunits), IL-6R, M-CSFR (c-fms), SCFR (c-kit), CD30, CD40, and TNFRs. Cytokines produced by H-RS cells might support the growth of tumor cells (autocrine growth loop) and/or interact with surrounding reactive bystander cells, particularly T cells. Conversely, H-RS cells might respond to cytokines produced by surrounding reactive normal cells (paracrine growth loop). The different interactions between H-RS cells and surrounding normal, reactive bystander cells, such as lymphocytes, plasma cells, histiocytes, neutrophils, eosinophils, and stromal cells, is characteristic for HD. The expression and biologic effects of a panel of cytokines and their counterpart receptors seem to be involved in the pathobiologic interaction between H-RS cells and particularly lymphocytes, mainly CD4.sup.+ T cells. Detailed analyses have to verify the predicted biologic activities of TNF, LT.alpha., CD27L, CD30L, CD40L, 4-1BBL, gp34/OX40L, and **FASL** for the H-RS cell/T-cell interactions with impact on tumor growth and pathogenesis of HD. Cytokines and cytokine receptors, including TNF/TNFRs, CD30/CD30L, and CD40/CD40L, are clearly critical elements in the pathology of HD and are part of the deregulated network of interactive signals between H-RS cells and surrounding bystander cells with membrane associated and cytokine mediated events. HD is a tumor of cytokine-producing cells that is causative for several characteristic clinical and pathologic presentation of HD. The functional role of cytokines for the pathogenesis

of NHLs is present unclear. Malignant NHL cells express, depending on their immunophenotype, several TNF receptor and ligand superfamily members. B-cell NHLs are frequently CD27/CD27L, CD30 or CD30L, CD40, and TNFRs/TNF positive, but T-cell NHLs have expression of CD30, CD40L, and TNFRs/TNF.

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.89	24.04

FILE 'REGISTRY' ENTERED AT 16:11:18 ON 09 JUN 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 JUN 2000 HIGHEST RN 269086-08-0
DICTIONARY FILE UPDATES: 8 JUN 2000 HIGHEST RN 269086-08-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> s ralepgp1s11clv1alpallpvp/sqsp

L19 5 RALEGPGLSLLCLVLALPALLPVP/SQSP

=> d sqn 1-5

L19 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2000 ACS
RN 254088-07-8 REGISTRY
CN Protein HDTEA84 (human precursor) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6: PN: WO0001817 SEQID: 6 claimed protein
FS PROTEIN SEQUENCE
SQL 300

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L19 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2000 ACS
RN 227948-98-3 REGISTRY
CN Protein TR2P-1 (tumor necrosis factor receptor type 2-like protein 1)
(human Incyte clone 1533650 N-terminal fragment) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 245

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L19 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2000 ACS
RN 221340-84-7 REGISTRY
CN [1-215]Tumor necrosis factor receptor 6.alpha. (human precursor) (9CI)
(CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 215

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L19 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2000 ACS
RN 210228-04-9 REGISTRY
CN Tumor necrosis factor receptor 6.beta. (human precursor) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE

SQL 170

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L19 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2000 ACS

RN 210227-94-4 REGISTRY

CN Tumor necrosis factor receptor 6.alpha. (human precursor) (9CI) (CA
INDEX

NAME)

OTHER NAMES:

CN Cytokine receptor TR6 (human T lymphocyte gene TR6 precursor)
CN Decoy receptor 3 (human gene DcR3 precursor)
CN DNA (human tumor necrosis factor receptor TR4 cDNA plus flanks)
CN Fas ligand receptor DcR3 (decoy receptor 3) (human gene DcR3 precursor)
CN GenBank AF104419-derived protein GI 4106878
CN GenBank AF134240-derived protein GI 4768939
CN GenBank AF217793-derived protein GI 6969261
CN GenBank AF217794-derived protein GI 6969263
CN M68C protein (human germ cell tumor alternatively spliced isoform 1)
CN M68E protein (human pancreas adenocarcinoma cell alternatively spliced
isoform 2)
CN Orphan receptor NTR-1 (human)
CN PN: WO9950413 FIGURE: 1a claimed protein
CN Protein (human lung tumor necrosis factor receptor homolog)
CN Receptor (human gene FLINT precursor)
CN Receptor DCR3 (decoy receptor 3) (human germ cell tumor alternatively
spliced isoform 1)
CN Receptor DCR3 (decoy receptor 3) (human pancreas adenocarcinoma cell
alternatively spliced isoform 2)
CN Receptor DcR3 (decoy receptor 3) (human precursor)
CN Receptor OPG-2 (human)
CN Tumor necrosis factor receptor (human lung)
CN Tumor necrosis factor receptor homolog (human lung)
CN Tumor necrosis factor receptor ZTNFR-5 (human precursor)
FS PROTEIN SEQUENCE
SQL 300

11 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
11 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> qalrvarmpglersvrerflpwh/sqsp

QALRVARMPGLERSVRERFLPWH IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s qalrvarmpglersvrerflpwh/sqsp

L20 0 QALRVARMPGLERSVRERFLPWH/SQSP

=> s qalrvarmpglersvrerflpwh/sqsf

L21 0 QALRVARMPGLERSVRERFLPWH/SQSFP

=> s sllclvlpallpv/sqsp

L22 5 SLLCLVLPALLPV/SQSP

=> s pavrgvaetptypwr/sqsp

L23 5 PAVRGVAETPTYPWR/SQSP

=> s lercrycnvlgere/sqsp

L24 7 LERCRYCNVLCGERE/SQSP

=> s fsasssssseqcqphr/s

L25 0 FSASSSSSEQCQPHR/SQSP

=> s nctalglalnvpqss/sqsp

L26 7 NCTALGLALNVPQSS/SQSP

=> sfsasssssseqsqphr/sqsp

SFSASSSSSEQSQPHR IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s sfsasssssseqsqphr/sqsp

L27 0 SFSASSSSSEQSQPHR/SQSP

=> s fsassssss

L28 0 FSASSSSSS

=> s fsassssss/sqsp

L29 0 FSASSSSSS/SQSP

=> s fvafqdisikrlqrl/sqsp

L30 6 FVAFQDISIKRLQRL/SQSP

=> d sqn 1-6

'L-6' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual
fields or predefined formats. The predefined substance formats
are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

Any CA File format may be combined with any substance format to
obtain CA references citing the substance. The substance formats
must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS --ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):sqn

L30 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2000 ACS
RN 254088-07-8 REGISTRY
CN Protein HDTEA84 (human precursor) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6: PN: WO0001817 SEQID: 6 claimed protein
FS PROTEIN SEQUENCE
SQL 300


1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d sqn 5-6

L30 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2000 ACS
RN 221150-00-1 REGISTRY
CN Tumor necrosis factor receptor APO6 (human precursor) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 215

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L30 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2000 ACS
RN 210227-94-4 REGISTRY
CN Tumor necrosis factor receptor 6.alpha. (human precursor) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Cytokine receptor TR6 (human T lymphocyte gene TR6 precursor)
CN Decoy receptor 3 (human gene Dcr3 precursor)
CN DNA (human tumor necrosis factor receptor TR4 cDNA plus flanks)
CN Fas ligand receptor Dcr3 (decoy receptor 3) (human gene Dcr3 precursor)
CN GenBank AF104419-derived protein GI 4106878
CN GenBank AF134240-derived protein GI 4768939
CN GenBank AF217793-derived protein GI 6969261
CN GenBank AF217794-derived protein GI 6969263
CN M68C protein (human germ cell tumor alternatively spliced isoform 1)
CN M68E protein (human pancreas adenocarcinoma cell alternatively spliced isoform 2)
CN Orphan receptor NTR-1 (human)
CN PN: WO9950413 FIGURE: 1a claimed protein
CN Protein (human lung tumor necrosis factor receptor homolog)
CN Receptor (human gene FLINT precursor)
CN Receptor DCR3 (decoy receptor 3) (human germ cell tumor alternatively spliced isoform 1)
CN Receptor DCR3 (decoy receptor 3) (human pancreas adenocarcinoma cell alternatively spliced isoform 2)
CN Receptor Dcr3 (decoy receptor 3) (human precursor)



CN Receptor OPG-2 (human)
CN Tumor necrosis factor receptor (human lung)
CN Tumor necrosis factor receptor homolog (human lung)
CN Tumor necrosis factor receptor ZTNFR-5 (human precursor)
FS PROTEIN SEQUENCE
SQL 300

11 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
11 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s caplus

L31 0 CAPLUS

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	288.86	312.90

FILE 'CAPLUS' ENTERED AT 16:24:10 ON 09 JUN 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 9 Jun 2000 VOL 132 ISS 24
FILE LAST UPDATED: 8 Jun 2000 (20000608/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

=> s fvafqdisikrlqrl/sqsp

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L33 15 L32

=> d ibib 1-15

L33 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 2000:99364 CAPLUS
DOCUMENT NUMBER: 132:249300
TITLE: Overexpression of M68/Dcr3 in human gastrointestinal tract tumors independent of gene amplification and its

AUTHOR(S):

Location in a four-gene cluster
Bai, Chang; Connolly, Brett; Ma, Michael L.;
Hilliard, Catherine A.; Liu, Xiaomei; Sandig, Volker;
Soderman, Avery; Galloway, Sheila M.; Liu, Qingyun;
Austin, Christopher P.; Caskey, C. Thomas

CORPORATE SOURCE:

Department of Human Genetics, Merck Research
Laboratories, West Point, PA, 19486-0004, USA
Proc. Natl. Acad. Sci. U. S. A. (2000), 97(3),
1230-1235

SOURCE:

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER:

National Academy of Sciences

DOCUMENT TYPE:

Journal

LANGUAGE:

English

REFERENCE COUNT:

41

REFERENCE(S):

(1) Akiyama, N; Cancer Res 1997, V57, P3548 CAPLUS
(2) Altschul, S; Nucleic Acids Res 1997, V25, P3389
CAPLUS
(5) Ashkenazi, A; Curr Opin Cell Biol 1999, V11, P255
CAPLUS
(6) Baker, S; Oncogene 1996, V12, P1 CAPLUS
(7) Bieche, I; Br J Cancer 1998, V78, P701 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 2 OF 15. CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER:

2000:34972 CAPLUS

DOCUMENT NUMBER:

132:89246

TITLE:

Mammalian genes encoding dendritic cell
prostaglandin-like transporter (DC-PGT), HDTEA84,
HSLJD37R and RANKL, HCC5 chemokine, deubiquitinating
11 and 12 (Dub11, Dub12), MD-1, MD-2 and cyclin E3
Bates, Elizabeth Esther Mary; Lebecque, Serge J. E.;
Murphy, Erin E.; Mattson, Jeanine D.; Gorman, Daniel
M.; Hedrick, Joseph A.; Wang, Luquan; Zlotnik,

INVENTOR(S):

Albert;

Murgolo, Nicholas J.; Greene, Jonathan R.; Johnston,
James A.; Bazan, Jose Fernando; Mahony, Daniel; Lees,
Emma M.

PATENT ASSIGNEE(S):

Schering Corporation, USA

SOURCE:

PCT Int. Appl., 218 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001817	A2	20000113	WO 1999-US12366	19990706
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, ZM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 1998-110938	19980706
			US 1998-114466	19980713
			US 1998-PV93897	19980723
			US 1998-132968	19980812
			US 1998-136214	19980818
			US 1998-PV99999	19980911

L33 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER:

1999:640984 CAPLUS

DOCUMENT NUMBER:

131:267554

TITLE:

FLINT: a new member of the tumor necrosis factor
receptor superfamily and its use in the treatment of
disease

INVENTOR(S):
Andrew

Bumol, Thomas Frank; Dou, Shenshen; Glasebrook,
Lawrence; Gould, Kenneth Elliot; Hale, John Edward;
Heuer, Josef Georg; Hui, Kwan Yuk; Kharitononkov,
Alexei; Mizrahi, Jacques; Na, Songqing; Noblitt,
Timothy Wayne; Reidy, Charles Arthur; Song, Ho Yeong;
Wang, Jian; Wu, Xiyang; Zuckerman, Steven Harold
Eli Lilly and Co., USA; et al.
PCT Int. Appl., 99 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9950413	A2	19991007	WO 1999-US6797	19990330
WO 9950413	A3	19991202		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9933691	A1	19991018	AU 1999-33691	19990330
PRIORITY APPLN. INFO.:			US 1998-PV79856	19980330
			US 1998-PV86074	19980520
			US 1998-PV99643	19980909
			US 1998-PV112577	19981217
			US 1998-PV112703	19981218
			US 1998-PV112933	19981218
			US 1998-PV113407	19981222
			US 1998-79856	19980330
			US 1998-86074	19980520
			US 1998-99643	19980909
			US 1998-112577	19981217
			US 1998-112703	19981218
			US 1998-112933	19981218
			US 1998-113407	19981222
			WO 1999-US6797	19990330

L33 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1999:595367 CAPLUS

DOCUMENT NUMBER: 131:209583

TITLE: Gene discovery of a new member of the tumor necrosis factor receptor superfamily of human lung and a cDNA encoding it

INVENTOR(S): Kroger, Burkhard

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9946376	A1	19990916	WO 1999-EP1252	19990226
W:	AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
DE 19809978	A1	19990916	DE 1998-19809978	19980309
AU 9929300	A1	19990927	AU 1999-29300	19990226

REFERENCE COUNT: 12

REFERENCE(S): (1) Aggarwal, B; European Cytokine Network 1996, V7(2), P93 CAPLUS
 (2) Ashkenazy; WO 9914330 A 1999
 (8) Gruss, H; Blood 1995, V85(12), P3378 CAPLUS
 (9) Gruss, H; International Journal of Clinical and Laboratory Research 1996, V26(3), P143 CAPLUS
 (11) Tan, K; Gene: An International Journal on Genes and Genomes 1997, V204(1-2), P35 MEDLINE
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1999:464085 CAPLUS

DOCUMENT NUMBER: 131:83468

TITLE: Mammalian tumor necrosis factor-like and tumor necrosis factor receptor-like proteins and cDNAs and methods for screening for apoptosis modulators
 INVENTOR(S): Tribouley, Catherine; Pot, David; Kassam, Altaf; Lamson, George

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933980	A2	19990708	WO 1998-US27474	19981222
WO 9933980	A3	19991118		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9920934	A1	19990719	AU 1999-20934	19981222
PRIORITY APPLN. INFO.:				
			US 1997-68959	19971230
			US 1998-212270	19981216
			WO 1998-US27474	19981222

L33 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1999:404988 CAPLUS

DOCUMENT NUMBER: 131:57782

TITLE: Human tumor necrosis factor receptor type 2-like proteins

INVENTOR(S): Bandman, Olga; Hillman, Jennifer L.; Au-Young, Janice;

Tang, Y. Tom; Kaser, Matthew R.

PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931128	A2	19990624	WO 1998-US25649	19981202
WO 9931128	A3	19991007		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

AU 9915416
PRIORITY APPLN. INFO.:

19990705

AU 1999-15416 19981202
US 1997-9919 19971216
WO 1998-US25649 19981202

L33 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:355802 CAPLUS
DOCUMENT NUMBER: 131:15462
TITLE: Receptor OPG-2 member of the tumor necrosis factor
receptor family and its diagnostic and therapeutic
applications
INVENTOR(S): Tschopp, Jurg
PATENT ASSIGNEE(S): Biogen, Inc., USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9926977	A1	19990603	WO 1998-US25065	19981124
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9915356	A1	19990615	AU 1999-15356	19981124
PRIORITY APPLN. INFO.:			US 1997-66446	19971124
			US 1998-74896	19980217
			WO 1998-US25065	19981124

REFERENCE COUNT: 5
REFERENCE(S): (1) Feng, P; WO 9830694 A 1998
(2) Masiakowski, P; WO 9907738 A 1999
(3) Simonet, W; Cell 1997, V89, P309 CAPLUS
(4) Smithkline Beecham Corp; EP 0861850 A 1998
(5) Zymogenetics Inc; WO 9904001 A 1999

L33 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:351865 CAPLUS
DOCUMENT NUMBER: 131:128872
TITLE: A newly identified member of tumor necrosis factor
receptor superfamily (TR6) suppresses LIGHT-mediated
apoptosis
AUTHOR(S): Yu, Kang-Yeol; Kwon, Byungsuk; Ni, Jian; Zhai, Yifan;
Ebner, Reinhard; Kwon, Byoung S.
CORPORATE SOURCE: Dep. Microbiology and Immunology and Walther Oncology
Center, Indiana Univ. School Medicine and Walther
Cancer Inst., Indianapolis, IN, 46202, USA
SOURCE: J. Biol. Chem. (1999), 274(20), 13733-13736
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular
Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 20
REFERENCE(S): (1) Armitage, R; Curr Opin Immunol 1994, V6, P407
CAPLUS
(2) Browning, J; J Exp Med 1996, V183, P867 CAPLUS
(3) Degli-Esposti, M; J Exp Med 1997, V186, P1165
CAPLUS
(4) Desbarats, J; Nat Med 1998, V4, P1377 CAPLUS
(5) Gruss, H; Blood 1995, V85, P3378 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:220056 CAPLUS

DOCUMENT NUMBER: 130:233277

TITLE: DcR3 polypeptide (tumor necrosis factor receptor homolog) and treatment of cancer with antibodies to DcR3

INVENTOR(S): Ashkenazi, Avi J.; Botstein, David; Dodge, Kelly H.; Gurney, Austin L.; Kim, Kyung Jin; Lawrence, David

A.;

Pitti, Robert; Roy, Margaret A.; Tumas, Daniel B.; Wood, William I.; Goddard, Audrey

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9914330	A1	19990325	WO 1998-US19661	19980918
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9894970	A1	19990405	AU 1998-94970	19980918
PRIORITY APPLN. INFO.:			US 1997-59288	19970918
			US 1998-94640	19980730
			WO 1998-US19661	19980918

REFERENCE COUNT: 4

REFERENCE(S):

- (1) Amgen Inc; WO 9723614 A 1997
- (2) Beutler, A; US 5447851 A 1995 CAPLUS
- (3) Human Genome Sciences Inc; WO 9830694 A 1998
- (4) Smithkline Beecham Corp; EP 0861850 A 1998

ACCESSION NUMBER: 1999:189208 CAPLUS

DOCUMENT NUMBER: 130:222136

TITLE: Mammalian tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents

INVENTOR(S): Chaudhary, Preet M.

PATENT ASSIGNEE(S): University of Washington, USA

SOURCE: PCT Int. Appl., 156 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911791	A2	19990311	WO 1998-US18393	19980904
WO 9911791	A3	19990930		
W:	AU, CA, JP			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
AU 9893764	A1	19990322	AU 1998-93764	19980904
PRIORITY APPLN. INFO.:			US 1997-924634	19970905
			WO 1998-US18393	19980904

ACCESSION NUMBER: 1999:126929 CAPLUS

DOCUMENT NUMBER: 130:192765
 TITLE: Cloning and cDNA sequences of human orphan receptor NTR-1
 INVENTOR(S): Masiakowski, Piotr J.; Morris, Jodi; Valenzuela, David
 PATENT ASSIGNEE(S): M. Regeneron Pharmaceuticals, Inc., USA; The Procter & Gamble Company
 SOURCE: PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9907738	A2	19990218	WO 1998-US16202	19980804
WO 9907738	A3	19990415		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9887676	A1	19990301	AU 1998-87676	19980804
PRIORITY APPLN. INFO.:			US 1997-54869	19970806
			WO 1998-US16202	19980804

L33 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1999:77688 CAPLUS
 DOCUMENT NUMBER: 130:152566
 TITLE: A new member of the tumor necrosis factor receptor family, ZTNFR-5, and a cDNA encoding it
 INVENTOR(S): Farrah, Theresa M.
 PATENT ASSIGNEE(S): Zymogenetics, Inc., USA
 SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9904001	A1	19990128	WO 1998-US15072	19980721
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9890139	A1	19990210	AU 1998-90139	19980721
PRIORITY APPLN. INFO.:			US 1997-53203	19970721
			WO 1998-US15072	19980721

REFERENCE COUNT: 5
 REFERENCE(S):
 (1) Amgen Inc; WO 9723614 A 1997
 (2) Beutler, B; US 5447851 A 1995 CAPLUS
 (3) Hillier; Database Genbank 1996
 (4) Human Genome Sciences Inc; WO 9830694 A 1998
 (5) Smithkline Beecham Corp; EP 0861850 A 1998

L33 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1999:24510 CAPLUS
 DOCUMENT NUMBER: 130:208170

TITLE: Genomic amplification of a decoy receptor for Fas
ligand in lung and colon cancer

AUTHOR(S): Pitti, Robert M.; Marsters, Scot A.; Lawrence, David
A.; Roy, Margaret; Kischkel, Frank C.; Dowd, Patrick;
Huang, Arthur; Donahue, Christopher J.; Sherwood,
Steven W.; Baldwin, Daryl T.; Godowski, Paul J.;
Wood,
William I.; Gurney, Austin L.; Hillan, Kenneth J.;
Cohen, Robert L.; Goddard, Audrey D.; Botstein,
David;
Ashkenazi, Avi

CORPORATE SOURCE: Departments of Molecular Oncology, Molecular Biology,
and Immunology, Genentech Inc., San Francisco, CA,
94080, USA

SOURCE: Nature (London) (1998), 396(6712), 699-703
CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Macmillan Magazines

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 24

REFERENCE(S): (1) Anderson, D; Nature 1997, V390, P175 CAPLUS
(2) Arase, H; J Exp Med 1995, V181, P1235 CAPLUS
(3) Ashkenazi, A; Curr Opin Immunol 1997, V9, P195
CAPLUS
(4) Ashkenazi, A; Science 1998, V281, P1305 CAPLUS
(5) Chicheportiche, Y; J Biol Chem 1997, V272, P32401
CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1998:537772 CAPLUS

DOCUMENT NUMBER: 129:202097

TITLE: Tumor necrosis factor receptor TR4 and clinical use

INVENTOR(S): Emery, John; Tung, Kon Bie; Tolnai, Aremseaji; Young,
Peter R.

PATENT ASSIGNEE(S): SmithKline Beecham Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10215886	A2	19980818	JP 1998-21908	19980203
US 5885800	A	19990323	US 1997-794796	19970204
CA 2220852	AA	19980803	CA 1998-2220852	19980119
EP 861850	A1	19980902	EP 1998-300382	19980120

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

PRIORITY APPLN. INFO.: US 1997-794796 19970204

L33 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1998:493682 CAPLUS

DOCUMENT NUMBER: 129:121654

TITLE: Tumor necrosis factor receptors 6.alpha. and 6.beta.
and the genes encoding them

INVENTOR(S): Gentz, Reiner L.; Ni, Jian; Ebner, Reinhard; Yu,
Guo-liang; Ruben, Steven M.; Feng, Ping

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; Gentz, Reiner L.;
Ni, Jian; Ebner, Reinhard; Yu, Guo-Liang; Ruben,
Steven M.; Feng, Ping

SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	ID	DATE	APPLICATION	DATE
WO 9830694	A2	19980716	WO 1998-US153	19980113
WO 9830694	A3	19981112		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG AU 9858157 A1 19980803 AU 1998-58157 19980113 PRIORITY APPLN. INFO.: US 1997-35496 19970114 WO 1998-US153 19980113				

=> d his

(FILE 'HOME' ENTERED AT 15:59:32 ON 09 JUN 2000)

FILE 'MEDLINE, BIOSIS' ENTERED AT 15:59:58 ON 09 JUN 2000

FILE 'MEDLINE, BIOSIS, BIOTECHNO' ENTERED AT 16:00:14 ON 09 JUN 2000

L1 6 S OSTEOPROTEGRIN
 L2 6 DUP REM L1 (0 DUPLICATES REMOVED)
 L3 2 S OPG3
 L4 1 DUP REM L3 (1 DUPLICATE REMOVED)
 L5 0 S TNFRSOL
 L6 5 S TNFR SOL?
 L7 2 DUP REM L6 (3 DUPLICATES REMOVED)
 L8 876 S FLINT
 L9 0 S L8 AND TNF
 L10 0 S L8 AND FAS
 L11 0 S L8 AND FASL
 L12 0 S L8 AND TNFR
 L13 3108 S FASL
 L14 15262 S FAS
 L15 2805 S L13 AND L14
 L16 64 S L15 AND TNFR
 L17 2 S L16 AND REVIEW
 L18 2 DUP REM L17 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 16:11:18 ON 09 JUN 2000

L19 5 S RALEGPGLSLLCLVLALPALLPVP/SQSP
 L20 0 S QALRVARMPGLERSVRERFLPWH/SQSP
 L21 0 S QALRVARMPGLERSVRERFLPWH/SQSFP
 L22 5 S SLLCLVLALPALLPV/SQSP
 L23 5 S PAVRGVAETPTYPWR/SQSP
 L24 7 S LERCRYCNVLCGERE/SQSP
 L25 0 S FSASSSSSSEQCQPHR/SQSP
 L26 7 S NCTALGLALNVP GSS/SQSP
 L27 0 S SFSASSSSSSEQSQPHR/SQSP
 L28 0 S FSASSSSSS
 L29 0 S FSASSSSSS/SQSP
 L30 6 S FVAFQDISIKRLQRL/SQSP
 L31 0 S CAPLUS

FILE 'CAPLUS' ENTERED AT 16:24:10 ON 09 JUN 2000
 S FVAFQDISIKRLQRL/SQSP

FILE 'REGISTRY' ENTERED AT 16:24:36 ON 09 JUN 2000
 L32 6 S FVAFQDISIKRLQRL/SQSP

FILE 'CAPLUS' ENTERED AT 16:24:39 ON 09 JUN 2000
 L33 15 S L32

=> s pgtfssas/sqsp

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L35 15 L34

=> s pgtfssasssss

L36 0 PGTFSSASSSSS

=> d his

(FILE 'HOME' ENTERED AT 15:59:32 ON 09 JUN 2000)

FILE 'MEDLINE, BIOSIS' ENTERED AT 15:59:58 ON 09 JUN 2000

FILE 'MEDLINE, BIOSIS, BIOTECHNO' ENTERED AT 16:00:14 ON 09 JUN 2000

L1 6 S OSTEOPROTEGRIN
L2 6 DUP REM L1 (0 DUPLICATES REMOVED)
L3 2 S OPG3
L4 1 DUP REM L3 (1 DUPLICATE REMOVED)
L5 0 S TNFRSOL
L6 5 S TNFR SOL?
L7 2 DUP REM L6 (3 DUPLICATES REMOVED)
L8 876 S FLINT
L9 0 S L8 AND TNF
L10 0 S L8 AND FAS
L11 0 S L8 AND FASL
L12 0 S L8 AND TNFR
L13 3108 S FASL
L14 15262 S FAS
L15 2805 S L13 AND L14
L16 64 S L15 AND TNFR
L17 2 S L16 AND REVIEW
L18 2 DUP REM L17 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 16:11:18 ON 09 JUN 2000

L19 5 S RALEGPGLSLLCLVLALPALLPVP/SQSP
L20 0 S QALRVARMPGLERSVRERFLPWH/SQSP
L21 0 S QALRVARMPGLERSVRERFLPWH/SQSFP
L22 5 S SLLCLVLALPALLPV/SQSP
L23 5 S PAVRGVAETPTYPPWR/SQSP
L24 7 S LERCRYCNVLCGERE/SQSP
L25 0 S FSASSSSSEQCQPHR/SQSP
L26 7 S NCTALGLALNVPGSS/SQSP
L27 0 S SFSASSSSSEQSQPHR/SQSP
L28 0 S FSASSSSSS
L29 0 S FSASSSSSS/SQSP
L30 6 S FVAFQDISIKRLQRL/SQSP
L31 0 S CAPLUS

FILE 'CAPLUS' ENTERED AT 16:24:10 ON 09 JUN 2000
S FVAFQDISIKRLQRL/SQSP

FILE 'REGISTRY' ENTERED AT 16:24:36 ON 09 JUN 2000
L32 6 S FVAFQDISIKRLQRL/SQSP

FILE 'CAPLUS' ENTERED AT 16:24:39 ON 09 JUN 2000
L33 15 S L32
S PGTFSSAS/SQSP

FILE 'REGISTRY' ENTERED AT 16:29:28 ON 09 JUN 2000
L34 8 S PGTF/SQSP

FILE 'CAPLUS' ENTERED AT 16:29:30 ON 09 JUN 2000
L35 15 S L34
L36 0 S PGTFSSASSSS

=> log y